Antigen loading of DCs with irradiated apoptotic tumor cells induces improved anti-tumor immunity compared to other approaches

被引:0
作者
Terry J. Fry
Jessica L. Shand
Matthew Milliron
Sarah K. Tasian
Crystal L. Mackall
机构
[1] Center for Cancer Research,Pediatric Oncology Branch
[2] NIH,undefined
来源
Cancer Immunology, Immunotherapy | 2009年 / 58卷
关键词
Dendritic cell vaccines; Cancer vaccines; Antitumor immunity;
D O I
暂无
中图分类号
学科分类号
摘要
Dendritic cells (DCs) serve as central regulators of adaptive immunity by presenting antigens and providing necessary co-signals. Environmental information received by the DCs determines the co-signals delivered to the responding adaptive cells and, ultimately, the outcome of the interaction. DCs loaded with relevant antigens have been used as therapeutic cellular vaccines, but the optimal antigen loading method has not been determined. We compared different methods to load class I and class II epitopes from the male antigenic complex, HY, onto DCs for the potency of the immune response induced in vivo. Co-incubation of female DCs with HY peptides, RNA or cell lysate from HY expressing tumor induced immune responses equivalent to male DCs. In contrast, female DCs incubated with irradiated, apoptotic HY expressing tumor cells (or male B cells) generated a stronger immune response than male DCs or female DCs loaded using any of the other methods. DC loading with apoptotic tumor resulted in complete protection against high dose HY-expressing tumor challenge whereas 100% lethality was observed in groups receiving DCs that were loaded with peptides, RNA, or lysate. We conclude that signals provided to the DCs by apoptotic cells substantially augment the potency of DC vaccines.
引用
收藏
页码:1257 / 1264
页数:7
相关论文
共 102 条
[1]  
Mellman I(2001)Dendritic cells: specialized and regulated antigen processing machines Cell 106 255-258
[2]  
Steinman RM(2005)Human dendritic cell subsets for vaccination J Clin Immunol 25 551-572
[3]  
Dubsky P(1999)Natural adjuvants: endogenous activators of dendritic cells Nat Med 5 1249-1255
[4]  
Ueno H(2004)Toll-like receptor control of the adaptive immune responses Nat Immunol 5 987-995
[5]  
Piqueras B(2002)Exploiting dendritic cells to improve vaccine efficacy J Clin Invest 109 1519-1526
[6]  
Connolly J(2006)Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer J Clin Oncol 24 3089-3094
[7]  
Banchereau J(2004)Cancer immunotherapy: moving beyond current vaccines Nat Med 10 909-915
[8]  
Palucka AK(2006)Dendritic cell-based immunotherapy Int Rev Immunol 25 377-413
[9]  
Gallucci S(2002)Characterization of an early dendritic cell precursor derived from murine lineage-negative hematopoietic progenitor cells Exp Hematol 30 430-439
[10]  
Lolkema M(2004)Escape from immune surveillance does not result in tolerance to tumor-associated antigens J Immunother 27 329-338